$MDWD

Fox David Morton purchased $142 of MDWD

Fox David Morton purchased 10 shares of MediWound Ltd. (MDWD) at $14.23 on 2026-06-01.

Original reporting
SEC EDGAR · Fox David Morton
Published Jun 2, 2026, 11:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 11:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MDWD
Bullish
medium confidence
Mentioned
$MDWD
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDWDBullishLow
01

Why it matters

The disclosure adds incremental sentiment information (director buying) but does not introduce new company fundamentals or forward-looking guidance.

02

Market read

This is a low-impact insider-buy signal with limited trading relevance absent other catalysts.

03

What to watch

No 10b5-1 plan was cited, but the disclosed size is tiny, so traders should weight it far less than upcoming clinical/data, financing, or partnership news.

Relevance 6/10Novelty 6/10Timing: Filed 2026-06-02; transaction dated 2026-06-01.

Background

The filing is an SEC Form 4 insider transaction disclosure for MediWound Ltd. (MDWD).

Company-level read

Ticker impact

$MDWDBullishMedium confidence
Context

Director Fox David Morton filed an open-market purchase of 10 shares at $14.23 on 2026-06-01, increasing direct holdings to 20,486.

Expected impact

Low likelihood of a material, immediate price move from this specific Form 4 alone.

Evidence & confidence

This is a disclosed insider transaction (Form 4) with a very small value ($142.30) and no accompanying corporate event (earnings, trial, deal, guidance).

Market effects

Minimal; this is company-specific insider activity with no stated sector/regulatory trigger.

None indicated.

None indicated.

Counterpoint

A small open-market buy can be routine (e.g., liquidity/plan mechanics) and may not reflect a new fundamental catalyst.

Key entities

  • MediWound Ltd.

    Subject of the Form 4 insider transaction; director purchased shares on 2026-06-01.

  • Fox David Morton

    Director who reported an open-market purchase of 10 shares at $14.23.

Related articles